216 related articles for article (PubMed ID: 26518752)
21. Reducible self-assembling cationic polypeptide-based micelles mediate co-delivery of doxorubicin and microRNA-34a for androgen-independent prostate cancer therapy.
Yao C; Liu J; Wu X; Tai Z; Gao Y; Zhu Q; Li J; Zhang L; Hu C; Gu F; Gao J; Gao S
J Control Release; 2016 Jun; 232():203-14. PubMed ID: 27126903
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-184 Modulates Doxorubicin Resistance in Osteosarcoma Cells by Targeting BCL2L1.
Lin BC; Huang D; Yu CQ; Mou Y; Liu YH; Zhang DW; Shi FJ
Med Sci Monit; 2016 May; 22():1761-5. PubMed ID: 27222034
[TBL] [Abstract][Full Text] [Related]
23. The Microtubule Network and Cell Death Are Regulated by an miR-34a/Stathmin 1/βIII-Tubulin Axis.
Vetter NS; Kolb EA; Mills CC; Sampson VB
Mol Cancer Res; 2017 Jul; 15(7):953-964. PubMed ID: 28275089
[TBL] [Abstract][Full Text] [Related]
24. Upregulation of miRNA-154-5p prevents the tumorigenesis of osteosarcoma.
Tian Q; Gu Y; Wang F; Zhou L; Dai Z; Liu H; Wu X; Wang X; Liu Y; Chen S; Han Q
Biomed Pharmacother; 2020 Apr; 124():109884. PubMed ID: 32000044
[TBL] [Abstract][Full Text] [Related]
25. Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression.
Sugiu K; Tazawa H; Hasei J; Yamakawa Y; Omori T; Komatsubara T; Mochizuki Y; Kondo H; Osaki S; Fujiwara T; Yoshida A; Kunisada T; Ueda K; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Cancer Chemother Pharmacol; 2021 Sep; 88(3):513-524. PubMed ID: 34114067
[TBL] [Abstract][Full Text] [Related]
26. Mir-34a: a regulatory hub with versatile functions that controls osteosarcoma networks.
Yang Z; Liu T; Ren X; Yang M; Tu C; Li Z
Cell Cycle; 2022 Oct; 21(20):2121-2131. PubMed ID: 35699451
[TBL] [Abstract][Full Text] [Related]
27.
Li PC; Tu MJ; Ho PY; Batra N; Tran MML; Qiu JX; Wun T; Lara PN; Hu X; Yu AX; Yu AM
Theranostics; 2021; 11(10):4858-4871. PubMed ID: 33754032
[No Abstract] [Full Text] [Related]
28. Synergistic growth inhibition by sorafenib and cisplatin in human osteosarcoma cells.
Yang Q; Zhang S; Kang M; Dong R; Zhao J
Oncol Rep; 2015 May; 33(5):2537-44. PubMed ID: 25738402
[TBL] [Abstract][Full Text] [Related]
29. Long noncoding RNA OIP5-AS1 mediates resistance to doxorubicin by regulating miR-137-3p/PTN axis in osteosarcoma.
Sun X; Tian C; Zhang H; Han K; Zhou M; Gan Z; Zhu H; Min D
Biomed Pharmacother; 2020 Aug; 128():110201. PubMed ID: 32460190
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA-187 suppresses the proliferation migration and invasion of human osteosarcoma cells by targeting MAPK7.
Liu M; Wu L; Cai C; Liu L; Xu Y
J BUON; 2020; 25(1):472-478. PubMed ID: 32277671
[TBL] [Abstract][Full Text] [Related]
31. miR-485-3p regulated by MALAT1 inhibits osteosarcoma glycolysis and metastasis by directly suppressing c-MET and AKT3/mTOR signalling.
Wang Q; Liu MJ; Bu J; Deng JL; Jiang BY; Jiang LD; He XJ
Life Sci; 2021 Mar; 268():118925. PubMed ID: 33358903
[TBL] [Abstract][Full Text] [Related]
32. Synergistic Effects of a Smac Mimetic with Doxorubicin Against Human Osteosarcoma.
Kamata E; Kawamoto T; Ueha T; Hara H; Fukase N; Minoda M; Morishita M; Takemori T; Fujiwara S; Nishida K; Kuroda R; Kurosaka M; Akisue T
Anticancer Res; 2017 Nov; 37(11):6097-6106. PubMed ID: 29061790
[TBL] [Abstract][Full Text] [Related]
33. Up-regulation of microRNA-496 suppresses proliferation, invasion, migration and in vivo tumorigenicity of human osteosarcoma cells by targeting eIF4E.
Qi NN; Tian S; Li X; Wang FL; Liu B
Biochimie; 2019 Aug; 163():1-11. PubMed ID: 30998968
[TBL] [Abstract][Full Text] [Related]
34. MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines.
Lopez CM; Yu PY; Zhang X; Yilmaz AS; London CA; Fenger JM
PLoS One; 2018; 13(1):e0190086. PubMed ID: 29293555
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA34a is associated with chemotherapy resistance, metastasis, recurrence, survival, and prognosis in patient with osteosarcoma.
Lian H; Zhou Y; Sun Z; Liu K
Medicine (Baltimore); 2022 Sep; 101(38):e30722. PubMed ID: 36197268
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of nuclear factor-κB by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells.
Castro-Gamero AM; Borges KS; da Silva Silveira V; Lira RC; de Paula Gomes Queiroz R; Valera FC; Scrideli CA; Umezawa K; Tone LG
Anticancer Drugs; 2012 Jul; 23(6):638-50. PubMed ID: 22382389
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-145 inhibits tumour growth and metastasis in osteosarcoma by targeting cyclin-dependent kinase, CDK6.
Li Y; Liu J; Liu ZZ; Wei WB
Eur Rev Med Pharmacol Sci; 2016 Dec; 20(24):5117-5125. PubMed ID: 28051259
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA‑487b‑3p inhibits osteosarcoma chemoresistance and metastasis by targeting ALDH1A3.
Cheng M; Duan PG; Gao ZZ; Dai M
Oncol Rep; 2020 Dec; 44(6):2691-2700. PubMed ID: 33125503
[TBL] [Abstract][Full Text] [Related]
39. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-34a inhibits human osteosarcoma proliferation by downregulating ether à go-go 1 expression.
Wu X; Zhong D; Gao Q; Zhai W; Ding Z; Wu J
Int J Med Sci; 2013; 10(6):676-82. PubMed ID: 23569431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
